Makers of drugs, medical devices and durable medical equipment, and the users of these products, are beginning to see supply chain disruptions as COVID-19, the disease caused by SARS-CoV-2, continues its march across the globe.
The FDA halted its inspections in China for February and has postponed, for now, many of its March inspections, stating on Feb. 24 that it is taking steps to ensure the safety of medical products as well as access to them. The agency also has reported its first shortage of a drug due to COVID-19, although it says there are alternatives.
In a statement released Feb. 14, FDA Commissioner Dr. Stephen Hahn wrote that the agency was being proactive. “We are not waiting for drug and device manufacturers to report shortages to us,” Hahn wrote, adding that the FDA has allocated additional resources to identify potential shortages related specifically to the SARS-CoV-2 outbreak and is coordinating with other international regulators.